Nvidia
December 1, 2021
Australia
December 1, 2021Vagus Nerve Stimulator and Getinge Approved
Vagus Nerve Stimulator Gets FDA Emergency OK for Asthmatics with COVID
People struck with COVID-19 display a broad range of symptoms. Some are hardly affected, while others experience terrible consequences. People with asthma are in particular danger, as SARS-CoV-2 is a respiratory virus that can cause breathing even more challenging.
The FDA has announced emergency authorization for the gammaCore Sapphire CV non-invasive Vagus nerve stimulator (nVNS) to support asthmatics with COVID-19 (or those presumed being affected) with breathing difficulties when medications are not suitable or lacking.
The gammaCore stimulator has been established as a therapy option for migraines and cluster headaches. However, it was initially studied as a method for managing reactive airway disorders such as asthma.
People struck with COVID-19 display a broad range of symptoms. Some are hardly affected, while others experience terrible consequences. People with asthma are in particular danger, as SARS-CoV-2 is a respiratory virus that can cause breathing even more challenging.
The FDA has announced emergency authorization for the gammaCore Sapphire CV non-invasive Vagus nerve stimulator (nVNS) to support asthmatics with COVID-19 (or those presumed being affected) with breathing difficulties when medications are not suitable or lacking.
The gammaCore stimulator has been established as a therapy option for migraines and cluster headaches. However, it was initially studied as a method for managing reactive airway disorders such as asthma.
The current Emergency Use Authorization, in a way, confirms that research. Previous investigations that assessed gammaCore for the acute treatment of asthma strengthen the belief that nVNS may provide much-needed relief for patients who have asthma-related breathing trouble, which can be particularly debilitating in victims with COVID-19,” said Peter Staats, MD. This may guide the Vagus nerve stimulator to be adopted more broadly for asthma and other reactive airway disorders in the future.(1,2,)
Getinge Servo-air Multi-Purpose Mechanical Ventilator FDA Cleared
Getinge has obtained FDA authorization for its Servo-air mechanical ventilator. The device does not require any wall gas or pressurized gas cylinders to work, thanks to a built-in turbine that produces sufficient continuous air pressure to meet any patient’s requirements. Utilizing powerful hot-swappable batteries provides the Servo-air with the energy necessary to sustain patients while in transportation between hospital departments.
The critical care ventilator is designed for pediatric and adult patients. It can be employed to provide invasive and non-invasive ventilation. This is an option for high-flow therapy that does not need any tube changes and can be easily selected on the Servo-air touchscreen.
Getinge has obtained FDA authorization for its Servo-air mechanical ventilator. The device does not require any wall gas or pressurized gas cylinders to work, thanks to a built-in turbine that produces sufficient continuous air pressure to meet any patient’s requirements. Utilizing powerful hot-swappable batteries provides the Servo-air with the energy necessary to sustain patients while in transportation between hospital departments.
The critical care ventilator is designed for pediatric and adult patients. It can be employed to provide invasive and non-invasive ventilation. This is an option for high-flow therapy that does not need any tube changes and can be easily selected on the Servo-air touchscreen.
It uses a technology called Servo Compass that maintains track of volume and pressure at each breath and so assists to limit lung injury from improper ventilation while following the ARDSnet protocol.
There is even an automatic method to move patients toward spontaneous breathing and weaning that automatically toggles between controlled and assisted ventilation, depending on whether the patients are breathing on their own. (3)